GPBAR1 and metabolic dysfunction-associated steatohepatitis: Wang et al. [111] investigated the therapeutic potential of the FXR and G protein-coupled receptor 5 (TGR5) axis in the treatment of non-alcoholic steatohepatitis (NASH) [111].